215 related articles for article (PubMed ID: 30633746)
1. Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model.
Emanuel A; Qiu H; Barker D; Takla T; Gillum K; Neimuth N; Kodihalli S
PLoS One; 2019; 14(1):e0209019. PubMed ID: 30633746
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Barker D; Gillum KT; Niemuth NA; Kodihalli S
PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
[TBL] [Abstract][Full Text] [Related]
4. Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.
Beliveau M; Anderson D; Barker D; Kodihalli S; Simard E; Hall C; Richardson JS
Clin Pharmacol Ther; 2022 Jul; 112(1):171-180. PubMed ID: 35467014
[TBL] [Abstract][Full Text] [Related]
5. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.
Snow DM; Cobb RR; Martinez J; Finger-Baker I; Collins L; Terpening S; Syar ES; Niemuth N; Kobs D; Barnewall R; Farr-Jones S; Marks JD; Tomic MT
Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33466411
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
7. Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.
Richardson JS; Parrera GS; Astacio H; Sahota H; Anderson DM; Hall C; Babinchak T
Clin Infect Dis; 2020 Apr; 70(9):1950-1957. PubMed ID: 31209461
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.
Tomic MT; Espinoza Y; Martinez Z; Pham K; Cobb RR; Snow DM; Earnhart CG; Pals T; Syar ES; Niemuth N; Kobs DJ; Farr-Jones S; Marks JD
Toxins (Basel); 2019 Apr; 11(4):. PubMed ID: 30959899
[TBL] [Abstract][Full Text] [Related]
9. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product.
Anderson DM; Kumar VR; Arper DL; Kruger E; Bilir SP; Richardson JS
PLoS One; 2019; 14(11):e0224700. PubMed ID: 31697731
[TBL] [Abstract][Full Text] [Related]
10. A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Diamant E; Pass A; Rosen O; Ben David A; Torgeman A; Barnea A; Tal A; Rosner A; Zichel R
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437616
[TBL] [Abstract][Full Text] [Related]
11. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
Cai S; Singh BR
Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic treatment of botulism with a clinically approved small molecule.
Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
14. Use of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) (BAT
Parrera GS; Astacio H; Tunga P; Anderson DM; Hall CL; Richardson JS
Toxins (Basel); 2021 Dec; 14(1):. PubMed ID: 35050996
[TBL] [Abstract][Full Text] [Related]
15. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.
Tomic MT; Farr-Jones S; Syar ES; Niemuth N; Kobs D; Hackett MJ; Espinoza Y; Martinez Z; Pham K; Snow DM; Marks JD; Cobb RR
Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564675
[TBL] [Abstract][Full Text] [Related]
17. Foodborne botulism treated with heptavalent botulism antitoxin.
Hill SE; Iqbal R; Cadiz CL; Le J
Ann Pharmacother; 2013 Feb; 47(2):e12. PubMed ID: 23362041
[TBL] [Abstract][Full Text] [Related]
18. A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.
Schwartz A; Ben David A; Hotoveli M; Dor E; Diamant E; Vivyorka A; Rosen O; Torgeman A; Zichel R
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0042121. PubMed ID: 33972251
[TBL] [Abstract][Full Text] [Related]
19. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Dembek ZF; Smith LA; Rusnak JM
Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
[TBL] [Abstract][Full Text] [Related]
20. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
Hatheway CH; Snyder JD; Seals JE; Edell TA; Lewis GE
J Infect Dis; 1984 Sep; 150(3):407-12. PubMed ID: 6481185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
